Pastures new for Bioxell's chief medical officer
Enrico Colli is set to leave his position as chief medical officer at biopharma business BioXell at the end of September and pursue a career at a large pharmaceutical organisation.
Enrico Colli is set to leave his position as chief medical officer at biopharma business BioXell at the end of September and pursue a career at a large pharmaceutical organisation.
His successor will be chief executive officer Francesco Sinigaglia, who will take over his functions on an interim basis until a permanent replacement is appointed.
"Enrico Colli has contributed significantly to the successful development of our company since he joined BioXell in 2002," said Sinigaglia. "I would like to acknowledge the excellent work Enrico has done in setting up the clinical programs for Elocalcitol, our lead compound. Today, Elocalcitol has the potential to become the monotherapy of choice for the treatment of lower urinary tract symptoms (LUTS) and could target a significant portion of both, the OAB and BPH markets. We all wish Enrico well in his future endeavours."
Colli said: "Being with BioXell has, from its very beginning until today, been very exciting. We made and are making substantial progress in the clinical development of BioXell's programs addressing unmet medical needs. While leaving the Company, I am proud of these accomplishments and I strongly believe that BioXell is on the right track to successfully complete development of its drug candidates."